Shares of Urogen Pharma (NASDAQ:URGN – Get Free Report) have received an average rating of “Moderate Buy” from the ten ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $50.3750.
Several research analysts have weighed in on URGN shares. Oppenheimer upped their price target on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research note on Thursday, July 16th. The Goldman Sachs Group reiterated a “neutral” rating and set a $44.00 price objective on shares of Urogen Pharma in a research report on Wednesday, July 15th. Guggenheim upped their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. UBS Group restated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a report on Friday, July 17th.
View Our Latest Analysis on URGN
Insider Transactions at Urogen Pharma
Institutional Trading of Urogen Pharma
Hedge funds have recently made changes to their positions in the business. Partners Capital Investment Group LLP purchased a new position in shares of Urogen Pharma in the 2nd quarter worth approximately $566,000. Rice Hall James & Associates LLC purchased a new stake in Urogen Pharma during the 2nd quarter valued at $11,064,000. California State Teachers Retirement System raised its holdings in Urogen Pharma by 1,605.5% during the 1st quarter. California State Teachers Retirement System now owns 38,750 shares of the company’s stock valued at $697,000 after buying an additional 36,478 shares during the period. Swiss National Bank bought a new stake in Urogen Pharma in the first quarter worth $1,399,000. Finally, SG Americas Securities LLC lifted its position in Urogen Pharma by 20.3% in the first quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock worth $29,808,000 after buying an additional 280,199 shares during the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.
Urogen Pharma Stock Down 4.1%
Shares of Urogen Pharma stock opened at $43.62 on Friday. The stock’s 50-day simple moving average is $41.81 and its 200-day simple moving average is $29.95. Urogen Pharma has a 52 week low of $15.86 and a 52 week high of $50.81. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of -22.03 and a beta of 1.57.
Urogen Pharma (NASDAQ:URGN – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. On average, equities analysts expect that Urogen Pharma will post -0.2 earnings per share for the current year.
About Urogen Pharma
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.
The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.
Featured Articles
- Five stocks we like better than Urogen Pharma
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
